Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy
Oliver Klein, Damien Kee, Ben Markman, Matteo S. Carlino, Craig Underhill, Jodie Palmer, D. Power, Jonathan Cebon, Andreas Behren
Topics & Concepts
PembrolizumabBiomarkerMedicineImmunotherapyOncologyCancerInternal medicineCancer researchBiologyBiochemistryCancer Immunotherapy and BiomarkersPancreatic and Hepatic Oncology ResearchLung Cancer Treatments and Mutations